Whether direct-acting antivirals (DAAs) increase the risk of hepatocellular carcinoma (HCC) recurrence after tumordirected therapy is controversial. We sought to determine the impact of DAA therapy on HCC recurrence after localregional therapy (LRT) and waitlist dropout among liver transplant (LT) candidates with HCC. We performed a retrospective cohort study of 149 LT candidates with hepatitis C virus (HCV) and HCC at a single center from 2014 through 2016. Cumulative incidence of HCC recurrence post-LRT and waitlist dropout was estimated by the DAA group. Factors associated with each outcome were evaluated using competing risks regression. A propensity score stabilized inverse probability weighting approach was used to account for differences in baseline characteristics between groups. The no DAA group (n 5 87) had more severe cirrhosis and lower rates of complete radiologic tumor response after LRT than those treated with DAA (n 5 62) but had similar alpha-fetoprotein and tumor burden at listing. Cumulative incidence of HCC recurrence within 1 year of complete response after LRT was 47.0% in the DAA group and 49.8% in the no DAA group (P 5 0.93). In adjusted competing risk analysis using weighted propensity score modeling, risk of HCC recurrence was similar in the DAA group compared to those without DAA (hazard ratio [HR], 0.91; 95% confidence interval [CI], 0.58-1.42; P 5 0.67). Patients treated with DAAs had lower risk of waitlist dropout due to tumor progression or death compared to the no DAA group in adjusted weighted analysis (HR, 0.30; 95% CI 0.13-0.69; P 5 0.005). Conclusion: In LT candidates with HCV and HCC with initial complete response to LRT, DAA use is not associated with increased risk of HCC recurrence but rather is associated with reduced risk of waitlist dropout due to tumor progression or death. (HEPATOLOGY 2018; 68:449-461).
D irect-acting antivirals (DAAs) have revolutionized the treatment of chronic hepatitis C virus (HCV), especially among patients with advanced disease. Safe and highly effective DAA therapies for patients with compensated or decompensated cirrhosis allow patients previously ineligible for antiviral therapy to be treated successfully. Benefits of achieving sustained virologic response (SVR) among patients with advanced liver disease include reversal of symptoms of decompensation, (1) improvement in Model for End-Stage Liver Disease (MELD) and Child-Pugh (CP) scores, (1) (2) (3) and reduced liver-related and all-cause mortality. (4) (5) (6) (7) In addition, HCV eradication with interferon (IFN)-based and DAA-based regimens has been associated with reduced rates of de novo hepatocellular carcinoma (HCC). (4, (7) (8) (9) (10) (11) However, for patients with HCV and HCC, the benefits of DAA therapy have been challenged by recent studies suggesting an increased risk of HCC recurrence after tumor-directed therapy. (12) (13) (14) HCC is a known complication for patients with HCV-associated cirrhosis. The annual incidence of de novo HCC after inducing SVR with DAA treatment has been variably reported to be 3%-5%, (9, 15) which is higher than that observed with IFN-based therapy (8, 9) but likely reflects treatment in a patient population with higher baseline risk of HCC (16) as current cohorts of patients treated with DAAs are typically older and have more advanced decompensation than previously treated IFN-based cohorts. (9, 17, 18) More controversial is whether there is higher risk of tumor recurrence in patients with HCC with complete response after curative HCV treatment. There are multiple hypotheses, all speculative, to explain the biological mechanism of increased HCC severity and risk of HCC recurrence with curative DAA therapy. One theory is that DAA treatment, by inducing rapid eradication of HCV, alters immune cancer surveillance, such that the balance between neoplastic cell proliferation and immune-induced cell death is disrupted. (9, 12, 13) In recent uncontrolled studies of patients with HCC treated with curative therapies (resection, radiofrequency ablation [RFA] , or liver transplantation [LT] ), the rates of HCC recurrence were estimated to be nearly 30% after 6 months, which the authors noted to be an unexpectedly high rate. (12) (13) (14) On the other hand, other studies, including one small study of patients on the LT waitlist, have not demonstrated an increased risk of HCC recurrence in patients treated with DAA or IFN-free regimens. (15, 19, 20) Ultimately, these findings have prompted significant commentary from the international community. (17, (21) (22) (23) Given that patients with HCC in the DAA era are likely different from their predecessors in the IFN era, controlled studies of sufficient sample size are necessary to shed light on this controversial issue. Additionally, because withholding of DAA treatment in patients with advanced liver disease and HCC may have negative consequences, including a higher risk of decompensation and death, studies on DAA therapy must consider the competing risks of death due to HCC recurrence and decompensated cirrhosis. In this study, we focused on patients on the LT waitlist with HCV and HCC, stratified by whether they received DAA therapy or not, and compared the rates of HCC recurrence after local-regional therapy (LRT) and waitlist dropout.
Patients and Methods

STUDY DESIGN AND PATIENT POPULATION
This is a retrospective cohort study of adult patients with HCV-associated cirrhosis and HCC who were listed for LT with MELD exception at the University of California, San Francisco (UCSF), from January 2014 to October 2016. Patients with tumor burden who exceeded Milan criteria but met criteria for the UCSF down-staging protocol (24, 25) were included once their tumor burden had been down-staged to within Milan criteria or had complete tumor response. Patients were grouped into two cohorts: those who were not treated with DAAs and those treated with DAAs. All patients had a history of HCC before starting DAA therapy. The study was conducted at a time when there were no concerns regarding adverse consequences of DAAs on HCC disease outcomes, so the decision to treat with DAAs was based on non-HCC criteria, namely anticipated time to transplantation, severity of liver and renal disease, and access to DAA therapy, which improved over the study period as newer DAA agents became available. This study was approved by the UCSF institutional review board.
MEASUREMENTS
A specific DAA regimen and treatment duration were selected for each patient according to viral genotype, severity of cirrhosis, and availability of specific drugs. If the patient received multiple courses of DAA therapy, data on both initial and most recent DAA regimens were collected. DAA treatment response was determined by SVR at 12 weeks, defined as undetectable HCV RNA at week 12 after the end of therapy. Other DAA treatment outcomes included completion of a full DAA regimen as prescribed, treatment up to the time of LT, or discontinuation of DAA therapy due to adverse events. CP class, MELD score, and alpha-fetoprotein (AFP) level within 3 months of initiation of DAA and 3 months after completion of DAA therapy were collected.
LRTs were used as bridge to LT, and due to longer waiting times at our center, LRTs were given with intent to achieve complete response. The LRTs used were trans-arterial chemoembolization (TACE), local ablation (RFA, cryotherapy, and ethanol injection), stereotactic body radiotherapy, and local surgical resection. The specific type of LRT performed for each patient was determined by a multidisciplinary tumor board, which consisted of transplant hepatologists and surgeons, oncologists, interventional radiologists, and diagnostic abdominal imaging radiologists. Repeated interventions were often performed to achieve complete necrosis of all tumor nodules. Response to LRT was made radiographically by either quadruple-phase computed tomography (CT) or magnetic resonance imaging (MRI) with gadolinium contrast. Complete tumor response to LRT was defined as the absence of residual tumor or complete necrosis according to modified response evaluation criteria in solid tumors. (26) HCC recurrence was diagnosed by arterial phase enhancement and washout during the delayed images on either CT or MRI with gadolinium contrast, to meet criteria for the Liver Imaging and Reporting Data System categories 4 and 5. (27) Criteria for HCC recurrence were also met if a lesion demonstrated interval growth with the same imaging technique or if clinical suspicion of tumor recurrence, as determined by the multidisciplinary tumor board, was high enough to recommend repeat LRT. Patients underwent abdominal CT or MRI at 1 month after each LRT and at a minimum of once every 3 months while on the LT waitlist. All imaging studies were reviewed by the multidisciplinary tumor board.
Dropout from the LT waitlist could occur for any of the following reasons: HCC tumor progression beyond Milan criteria, death without LT, being too sick or medically unsuitable to undergo LT, noncompliance, patient decision not to undergo LT, or being lost to follow-up.
For patients who underwent LT, explant histopathologic characteristics were evaluated. These included the presence or absence of viable HCC on explant, histologic grade of differentiation based on the Edmondson and Steiner criteria (grade 1, well differentiated; grade 2, moderately differentiated; grade 3, poorly differentiated), (28) the presence or absence of microvascular or macrovascular invasion, and pathologic tumor stage, based on the United Network for Organ Sharing tumor-node-metastasis staging system. (29) 
OUTCOMES AND STATISTICAL ANALYSIS
The primary outcomes of interest were probability of HCC recurrence after complete response and waitlist dropout secondary to tumor progression or liverrelated death. Secondary endpoints included rates of LT and overall intention-to-treat survival. The exposure of interest was DAA therapy, with two groups compared: patients who were not treated with DAAs (no DAA group) and those treated with DAAs (DAA group). Baseline patient, tumor, and explant characteristics were summarized by DAA exposure group using medians and interquartile ranges (IQRs) for continuous variables and proportions for categorical variables. The Pearson chi-squared and Wilcoxon rank sum tests were used to assess differences between groups, and the Wilcoxon signed-rank test was used to assess differences in pre-DAA versus post-DAA therapy lab values.
In observational studies, systematic differences in baseline characteristics of treatment groups may introduce confounding and limit direct comparison of treatment effects. (30) Therefore, we applied propensity score methods to address selection bias and reduce related confounding. (30) We estimated the propensity score for the probability of receiving DAA treatment using logistic regression. Baseline pretreatment characteristics that were unbalanced between DAA treatment groups or expected to impact selection to DAA treatment (AFP, down-staging, complete response to LRT, CP class, and MELD) were included in the propensity score model. The inverse probability of treatment weights (IPTW) was calculated for each subject from the propensity score and stabilized to avoid extreme weights and reduce variance. (31, 32) Weighted, rather than matching, propensity score methods were used due to our relatively small sample with unequal treatment group sizes, allowing for inclusion of all study subjects in the analysis. To determine if adequate balance was achieved through propensity score weighting, we evaluated the standardized differences (33) in baseline characteristics included in the propensity score for the unweighted and weighted DAA treatment groups.
Primary and secondary waitlist outcomes were evaluated using Fine and Gray competing risk regression. (34) For HCC recurrence analyses, patient followup time was measured starting at the date of complete response with LRT to the date of HCC recurrence, other waitlist events (dropout due to tumor progression, liver-related death, or LT), or last follow-up. For waitlist dropout and LT analyses, patient follow-up time was measured from the date of HCC MELD exception listing to the date of the waitlist event (dropout due to tumor progression, liver-related death, or LT) or last follow-up. Waitlist outcomes other than the event of interest were treated as competing risks. For HCC recurrence, liver-related death and LT were modeled as competing events. For waitlist dropout, LT was modeled as a competing event. For LT, dropout due to tumor progression and liver-related death were modeled as competing events. Follow-up was censored at delisting for patients removed from the waitlist due to developing nonliver disease medical contraindication to LT, noncompliance with UCSF transplant policies, or loss of interest in LT.
The cumulative incidence and 95% confidence intervals (CI) for HCC recurrence, waitlist dropout, and LT were estimated while accounting for competing risks and evaluated by DAA exposure. Using Fine and Gray competing risk regression, (34) univariate subhazard ratios (HRs) and 95% CIs for the association of explanatory variables for risk of HCC recurrence, waitlist dropout, and LT were calculated. Explanatory variables with a prespecified statistical significance of P < 0.1 were included in the multivariable analysis. The final model was selected by backward elimination (P for removal > 0.05), while retaining biologically plausible variables, as well as DAA treatment group as the primary variable of interest. Parallel analyses using unweighted and weighted (propensity score-stabilized IPTW) methods were conducted.
Intention-to-treat survival and 95% CIs were estimated using the Kaplan-Meier method and applying the propensity score-stabilized IPTW, both overall and stratified by DAA treatment group. Follow-up time was measured from the date of HCC diagnosis to the date of death (while on waitlist or post-LT) or last study follow-up. The modified log-rank test for weighted samples (30) was used to compare survival estimates by DAA group. Statistical analyses were performed using SAS v9.4 and Stata/IC 14.
Results
PATIENT CHARACTERISTICS
A total of 149 patients met inclusion criteria ( MELD exception, median MELD score was 10 (IQR, [8] [9] [10] [11] [12] [13] for the overall population. The no DAA group had a higher median MELD score at listing (12; IQR, 8-15) compared to those treated with DAAs (9; IQR, 7-11; P < 0.001).
With regard to tumor characteristics at listing, median AFP (16.4 ng/mL; IQR, 6.6-55.4) was similar between groups (P 5 0.92). There was also no difference in initial tumor burden, as characterized by the size of the largest lesion (P 5 0.36), the number of HCC lesions (P 5 0.32), or the proportion of patients who were down-staged to Milan criteria (P 5 0.65). Overall, 144 of 149 patients (96.6%) received at least one LRT and 79 (53.0%) received three or more LRTs. There was a similar distribution of number of LRTs received among the two groups (P 5 0.14).
For the overall cohort, median follow-up time from HCC diagnosis to death or last follow-up was 27. Overall, 120 of 149 patients (80.5%) achieved complete tumor response after LRT. In these 120 patients, the median number of LRTs required to achieve complete response was 1 (IQR, 1-2). Those without DAA therapy were less likely to achieve complete tumor response after LRT (67.8%) compared to the DAA group (98.4%, P < 0.001). Overall, TACE was the most common LRT used to achieve complete response, including when used alone (63.3%) or in combination with RFA (20.0%). There was no difference in either the number (P 5 0.73) or type (P 5 0.54) of LRT required to achieve complete response between the groups (Table 1) .
Most patients had HCV genotype 1 infection (66.9%). Patients who did not receive DAA therapy were more likely to have HCV genotype 3 (32.5%) compared to those treated with DAAs (14.5%, P 5 0.02). The specific DAA regimens used and associated baseline characteristics are shown in Supporting Table  S1 . Thirteen percent of patients received more than one course of DAA therapy. The median time between HCC diagnosis and DAA therapy was 11.9 months (IQR, 6.9-19.6). The median duration of latest DAA therapy received was 3.1 months (IQR, 2.8-5.6). Of patients who received DAA therapy, 77.4% (48/62) achieved SVR at 12 weeks. Overall, 21.3% (13/61) of patients received DAAs up to the time of LT.
With DAA treatment, median AFP decreased from 21.0 ng/mL (IQR, 9.1-55.4) before receiving DAA (measured within 3 months prior to DAA initiation) to 8.1 ng/mL (IQR, 4.6-18.5) after receiving DAAs (measured within 3 months after completion of DAA therapy) (P 5 0.01). Median MELD scores were similar pre-DAA therapy (9; IQR, 7-10) compared to post-DAA therapy (9; IQR, 8-11; P 5 0.09). There was no difference in median CP score before (6; IQR, 5-7) compared to after (6; IQR, 5-7; P 5 0.39) receiving DAA therapy.
Variables that were imbalanced between DAA treatment groups or expected to impact selection to DAA treatment were AFP, down-staging, complete response to LRT, CP class, and MELD, which were included in the propensity score model (Supporting Table S2 ). After applying propensity score-stabilized IPTW techniques, the standard differences in covariate means were <10%, improved substantially from unweighted standard differences.
HCC RECURRENCE AFTER COMPLETE RESPONSE TO LRT
Of 120 patients who achieved complete response to LRT, 73 experienced HCC recurrence after a median of 6.0 months (IQR, 3.5-11.7). The median time from complete response to HCC recurrence in the no DAA group was 5.5 months (IQR, 3.1-7.6) compared to 8.2 months (IQR, 3.7-12.8) in the DAA group (P 5 0.09).
The overall cumulative 6-month and 1-year incidence rates of HCC recurrence after complete response with LRT were 31.6% (95% CI, 23.4-40.0) and 48.7% (95% CI, 39.3-57.5) (Fig. 2A) . No statistically significant difference was detected in cumulative probability of HCC recurrence within 1 year between the two groups: 47.0% (95% CI, 32.4-60.3) for the DAA group and 49.8% (95% CI, 37.4-61.1) for the no DAA group (P 5 0.93).
Unweighted univariate and multivariate analyses for HCC recurrence after complete response are shown in Supporting Table S3 . In unweighted univariate competing risk models, the DAA group had similar risk of HCC recurrence compared to patients without DAA therapy (HR, 0.96; 95% CI, 0.61-1.51; P 5 0.86). In unweighted multivariable analysis, adjusted for number of LRTs and initial tumor burden (number of HCC lesions at listing), risk of HCC recurrence remained similar for the DAA group compared to patients without DAA (HR, 0.91; 95% CI, 0.56-1.45; P 5 0.68).
Propensity score-weighted analysis in both univariate and multivariate models (Table 2 ) demonstrated similar findings to unweighted analysis. Covariates included in the propensity score (AFP, down-staging, complete response to LRT, CP class, and MELD) were not assessed in weighted modeling. The weighted multivariate model was adjusted for number of LRTs received. The DAA group had similar risk of HCC recurrence as the no DAA group in weighted univariate competing risk analysis (HR, 1.02; 95% CI, 0.65-1.60; P 5 0.93) as well as in weighted multivariate competing risk analysis (HR, 0.91; 95% CI, 0.58-1.42; P 5 0.67). Lower number of LRTs received was also associated with decreased risk of HCC recurrence in both weighted univariate (HR, 0.20; 95% CI, 0.08-0.53; P 5 0.001) and multivariate (HR, 0.20; 95% CI, 0.08-0.52; P 5 0.001) models.
WAITLIST DROPOUT
Overall, 20 out of 149 patients experienced dropout due to tumor progression, and an additional 16 patients died while on the waitlist. The median time from listing with MELD exception to waitlist dropout due to tumor progression or liver-related death was 7.2 months (IQR, 5.1-12.4).
FIG. 2. (A)
Weighted cumulative incidence of HCC recurrence after complete response by the DAA group. Weighted using propensity score stabilized IPTW. (B) Weighted cumulative incidence of waitlist dropout due to tumor progression or death by the DAA group. Weighted using propensity score stabilized IPTW. (C) Weighted cumulative incidence of LT by the DAA group. Weighted using propensity score stabilized IPTW.
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The overall cumulative probability of waitlist dropout related to tumor progression or death after listing with MELD exception was 7.9% within 6 months (95% CI, 4.2-13.1) and 16.1% within 1 year (95% CI 10.6-22.7) (Fig. 2B) . The 1-year cumulative incidence of dropout was significantly lower for the DAA group at 5.9% (95% CI, 1.8-13.7), compared to 24.0% (95% CI, 15.2-33.9) in the no DAA group (P 5 0.005). Patients in the DAA group were required to survive until time of DAA therapy, potentially resulting in biased dropout estimates. For this reason, we also estimated dropout in this group with observation time starting at time of DAA treatment initiation, with a similar estimate of 1-year cumulative incidence of waitlist dropout (4.2%; 95% CI, 0.0.9-11.5). In an alternative analysis to adjust for this survival bias, the median time from listing to DAA initiation (5.1 months) was added to dropout times in the no DAA group, which resulted in a slightly lower 1-year cumulative incidence of dropout in the no DAA group (19.7%; 95% CI, 11.9-29.0). However, the DAA group still had significantly lower 1-year cumulative incidence of dropout compared to the no DAA group in this adjusted analysis (P 5 0.001).
In unweighted univariate competing risk models, those in the DAA group had a significantly decreased risk of dropout compared to those who did not receive DAA (HR, 0.20; 95% CI, 0.09-0.48; P < 0.001) (Supporting Table S4 ). In unweighted multivariable analysis, adjusted for CP class, patients who received DAAs had decreased risk of waitlist dropout (HR, 0.24; 95% CI, 0.10-0.59; P 5 0.002), and those with CP class C (versus A) at listing had significantly increased risk of dropout (HR, 2.62; 95% CI, 1.03-6.69; P 5 0.04).
Propensity score-weighted analysis in both univariate and multivariate models (Table 3) demonstrated similar findings as unweighted analysis. The DAA treatment group was the only variable included in the weighted multivariate model because all other covariates, as seen in Table 3 , were removed by backward elimination or were not eligible for evaluation in the multivariate model (univariate P > 0.1). Patients treated with DAAs had decreased risk of waitlist dropout compared to the no DAA group in weighted univariate competing risk analysis (HR, 0.30; 95% CI, 0.13-0.69; P 5 0.005), with no additional covariates that were statistically significant in the multivariate model.
LT
Of the 149 patients, 76 underwent LT a median of 15.7 months (IQR, 8.6-19.0) after listing with MELD exception. The overall cumulative incidence of LT was 18.1% (95% CI, 12.2-25.0) within 1 year and 71.2% (95% CI, 62.0-78.6) within 2 years (Fig. 2C) . The cumulative incidence of LT within 1 year was 14.2% (95% CI, 6.9-24.2) for the DAA group and 21.0% (95% CI, 12.8-30.6) in the no DAA group (P 5 0.42). 
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In unweighted univariate competing risk models, there was no statistically significant difference in the probability of LT in the DAA group compared to those not treated with DAAs (HR, 1.27; 95% CI, 0.82-1.96; P 5 0.28) (Supporting Table S5 ). By unweighted multivariate competing risk analysis, adjusted for blood type, number of LRTs, and initial tumor burden (multiple HCC lesions at listing), there was also no statistically significant difference in rate of LT in the DAA group compared to patients not treated with DAA therapy (HR, 1.39; 95% CI, 0.85-2.28; P 5 0.19).
Propensity score-weighted analysis in both univariate and multivariate models (Supporting Table S6 ) demonstrated similar findings as unweighted analysis. There was no difference in the probability of LT in the DAA group compared to those who did not receive DAAs in weighted univariate analysis (HR, 1.19; 95% CI, 0.78-1.80; P 5 0.42) and in weighted multivariate analysis (HR, 1.21; 95% CI, 0.76-1.92; P 5 0.42), which was adjusted for number of LRTs and initial tumor burden.
Explant histopathologic characteristics for LT recipients are summarized in Supporting Table S7 . Complete necrosis with no residual viable tumor as a result of LRT was seen in 24.0% of explants (18/75). Viable tumors were within Milan criteria in 52.0% of explants (39/75), and microvascular invasion was present in 8.0% of explants (6/75). Among patients with viable tumors in the explant, 32.1% (18/56) had well-differentiated HCC and 57.1% (32/56) had moderately differentiated HCC. Compared to the no DAA group, a higher proportion of patients treated with DAAs had poorly differentiated HCC (13.2% versus 2.8%, P 5 0.26) and vascular invasion (15.4% versus 2.8%, P 5 0.15), though these differences were not statistically significant. Overall, AFP at LT (P 5 0.29) and presence of viable tumor on explant (P 5 0.67) were similar among those who received DAAs and those who did not. 
INTENTION-TO-TREAT SURVIVAL
Overall, patients were followed for a median of 27.3 months (IQR, 17.6-35.1) from HCC diagnosis to death or last study follow-up, including the post-LT period. On an intention-to-treat analysis, survival for the entire study population was 92.1% (95% CI, 83.4-96.4) at 1 year and 89.6% (95% CI, 80.1-94.7) at 2 years from HCC diagnosis (Fig. 3) . When stratified by DAA group, overall weighted survival was similar in the DAA group compared to those who did not receive DAA therapy (P 5 0.08).
Discussion
With the advent of effective and safe antiviral therapies for patients with advanced cirrhosis, most patients on the LT waitlist can be offered a chance at HCV cure; but the decision to treat is complex, such that potential benefits as well as harms must be taken into account. Current guidelines recommend DAA therapy for patients with HCC on the waiting list, (35) though this practice is controversial. Uncontrolled studies among patients with HCC with complete response to LRT reported higher than expected HCC recurrence rates in the setting of subsequent DAA therapy. (12, 13) Our study uniquely focused on the waitlisted patient population and used a contemporaneous untreated control group to better assess the benefits versus harms of DAA therapy. Additionally, recognizing that differences in severity of cirrhosis and other key baseline characteristics may influence outcomes on the waiting list, we used a propensity-weighted approach. We found no negative association between DAA therapy and HCC recurrence among waitlisted patients. For this reason, our results lend strong support to the use of DAA therapy in waitlisted patients with HCC who have achieved complete response with LRT.
The controversy over the use of DAA therapy in patients with HCV and HCC is partially fueled by early studies that suffered from limitations of study design and sample size. (12) (13) (14) Most important among the limitations was the lack of controls or the use of IFN-treated controls. Differences in baseline characteristics between DAA-treated and IFN-treated patients make comparisons with historical treated controls suboptimal. (12, 13) Several recent publications in HCV-infected patients with HCC have highlighted that DAA-treated cohorts are older and have more advanced cirrhosis, leading to higher baseline rates of HCC and likely influencing HCC recurrence rates after LRT. (9, 17) In more recent studies using contemporaneous controls, as was done in our study, no increased risk of de novo HCC or recurrent HCC after curative therapy was seen. (15, 18, 19) Our study focused on the waitlisted patient population, and while these patients are likely to have more advanced liver disease compared to other studies, our findings align with these recent cohort studies that found no association between DAA therapy and higher risk of HCC recurrence after curative LRT.
Due to long waiting times for patients with HCC at our center, our study of waitlisted patients presents a unique opportunity to evaluate potential benefits versus harms of DAA therapy in patients with cirrhosis and HCC, including those with decompensation. Among our patients listed with HCC exception status, approximately half had CP B or C cirrhosis, with significant risk of death due to worsening decompensation that may be modified by HCV eradication. Thus, understanding the contributions of DAA therapy to both HCC and cirrhosis outcomes is critical in guiding DAA use in the HCC population. In weighted propensity score modeling to adjust for differences in baseline characteristics, we found that DAA therapy was associated with a 70% reduction in waitlist dropout due to tumor progression or liver-related death. We speculate that patients who received DAA therapy benefited by stabilization of liver function and reduced risk of decompensating events. These findings align with previous literature showing that DAA therapy is associated with improvement in MELD and CP scores within 12-24 weeks of treatment (1) (2) (3) 15) as well as lower rates of decompensation. (1, 15) Thus, when assessing the use of DAA therapy in patients with HCC, these additional benefits must be considered.
HCC management in the transplant setting was evaluated in another single-center study from Italian investigators, with 23 DAA-treated patients compared to 23 untreated contemporaneous controls. (20) Though the sample size was smaller, similar trends were seen as in our study, with no significant differences in rate of waitlist dropout due to HCC progression, in addition to similar explant pathology as measured by number of HCC nodules and total tumor volume, stage of differentiation, and presence of microvascular invasion between treated and untreated patients. In addition, there was no difference in post-LT HCC recurrence (12.5%, 1/8 patients in DAA group) compared to 8.3% (1/12 in untreated group). (20) These results contrast with those of a Mayo Clinic study that reported a greater proportion of explants outside Milan criteria and a trend toward higher post-LT HCC recurrence rates in patients treated with DAAs versus those not treated with DAAs (5/18 versus 6/63 patients), although differences in waiting time and post-LT follow-up limit interpretation of these results. (14) We did not evaluate posttransplant outcomes in our study due to the limited duration of follow-up time available post-LT, but this is an important future area of investigation.
Patients received a wide range of bridging LRTs, but TACE was the predominant therapy used in our program. This highlights an important difference between the present study and previously published literature analyzing HCC recurrence risk after complete response to either surgical resection or ablation followed by DAAs. TACE is the most commonly used treatment modality on the LT waitlist, typically employed when the expected wait time is at least 6 months. (36) While TACE is not thought to be curative, it is applicable across a broader spectrum of waitlisted patients than other LRTs such as RFA, and high rates of complete response were seen in the present study. There were no differences observed in either number or type of LRTs required to achieve complete response in the two groups. Overall, 80% of our patient population achieved initial complete response after LRT, with worse rates observed in those without DAA therapy, potentially explained by worse liver function in this group, leading to less aggressive LRT. The overall cumulative incidence of HCC recurrence after complete response with LRT was 32% within 6 months and 49% within 1 year. These results compare favorably with an Italian study involving 148 patients with a single nodule treated only with TACE, in which nearly two thirds of patients had tumor recurrence at a median of 9 months after initial complete response. (37) Our study has some limitations. This is a singlecenter, observational study, and assignment of DAA therapy was not randomized. Thus, untreated patients tended to have more severe baseline cirrhosis and were less likely to achieve complete tumor response with LRT. To address these differences, we performed weighted analysis with propensity scores. There is also potential bias in the DAA group, such that patients treated with DAA had to survive long enough to receive DAA therapy. We addressed this potential bias by analyzing cumulative incidence of waitlist dropout with observation time starting at time of DAA initiation, rather than at time of listing. In addition, overall median wait time from listing with MELD exception to LT was 16 months; the benefits of DAA therapy may be influenced by wait times, with longer wait times providing the opportunity to both complete DAA therapy and derive benefit from clinical improvement. There are multiple additional factors to take into account when deciding on the optimal timing of DAA initiation in a patient with HCC. Delaying DAA therapy until after complete response to LRT may increase SVR rates, (38) but if a patient has advanced or worsening hepatic decompensation, DAA therapy may stabilize the liver disease, allowing for additional LRT if needed and decreasing the risk of waitlist dropout due to liver-related death. Finally, the decision to treat with DAAs should take into account regional availability and use of HCV-positive donors. (39) Additional studies are needed, but, as highlighted by our study, future studies need to consider potential harms versus benefits of DAA therapy in patients with HCC.
In conclusion, we did not find an association between DAA use and increased risk of HCC recurrence after complete response to LRT in patients with HCV-associated cirrhosis and HCC on the LT waitlist. Our results argue against recent literature that suggests that DAA therapy promotes HCC recurrence. Moreover, we show that DAA treatment is associated with reduced waitlist dropout due to tumor progression or death and that DAA use is not associated with decreased probability of LT or overall survival. Ultimately, the decision to treat HCV in waitlisted patients needs to be individualized, but our study provides support for the use of DAA therapy in patients on the transplant waiting list with HCC who have achieved initial response to LRT.
